Michel Farnier
Michel Farnier is an expert in Cardiology at University of Burgundy (France). As of July 2026, ScienceLeadR ranks Michel Farnier in the top 1% of experts worldwide for Hypercholesterolemia, Hyperlipidemias and Dyslipidemias. Michel Farnier has authored 245 publications, the most recent in 2026, and is an investigator in 15 clinical trials. SLR score: 743 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Endocrinology - Immunology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1983 - 2026
Number : 245
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Leukocyte activation and inflammation in acute myocardial infarction: novel insights from cell population data. PMID 42490811 — cells, mortality, monocytes, myocardial infarction, neutrophils, biomarkers, immune system diseases, leukocytes, fatty acids | Front Immunol | 2026 | 0 |
| Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins. PMID 42325672 — diabetes mellitus, cholesterol, ldl, lipoproteins, dyslipidemias, cholesterol, risk factors, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, triglycerides, fenofibrate | Front Cardiovasc Med | 2026 | 0 |
| Dosage of lipoproteins for risk management according to guidelines. PMID 42203612 — research design, cholesterol, ldl, lipoproteins, risk management, therapeutics | Vasc Dis (Paris) | 2026 | 0 |
| Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINI. PMID 41908045 — cholesterol, ldl, cohort studies, therapeutics | Front Cardiovasc Med | 2026 | 0 |
| Not all fibrates are made equal: Learning from biology and clinical trials. PMID 41172702 — cholesterol, ldl, lipoproteins, dyslipidemias, cholesterol, therapeutics, learning, hydroxymethylglutaryl-coa reductase inhibitors, fenofibrate | Atherosclerosis | 2025 | 1 |
Clinical Studies 15
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
LeadR Networks
Main global connection map